KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaboration Revenue BreakdownCollaboration Revenue Breakdown AnnualContractual ObligatonsCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Provision For Income TaxNon Gaap ExpensesNon Gaap Expenses AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProduct Revenue Breakdown AnnualProperty And Equipment, Net BreakdownRevenue By ProductRevenue By Product %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Pmo Product Revenues, Net BreakdownTotal Pmo Product Revenues, Net Breakdown Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Gross Profit: 2011-2024

Historic Gross Profit for Sarepta Therapeutics (SRPT) over the last 14 years, with Dec 2024 value amounting to $1.6 billion.

  • Sarepta Therapeutics' Gross Profit rose 48.73% to $473.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.5 billion, marking a year-over-year increase of 11.92%. This contributed to the annual value of $1.6 billion for FY2024, which is 44.82% up from last year.
  • Sarepta Therapeutics' Gross Profit amounted to $1.6 billion in FY2024, which was up 44.82% from $1.1 billion recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Gross Profit ranged from a high of $1.6 billion in FY2024 and a low of $476.7 million during FY2020.
  • Its 3-year average for Gross Profit is $1.2 billion, with a median of $1.1 billion in 2023.
  • Data for Sarepta Therapeutics' Gross Profit shows a peak YoY soared of 47.02% (in 2020) over the last 5 years.
  • Sarepta Therapeutics' Gross Profit (Yearly) stood at $476.7 million in 2020, then grew by 26.88% to $604.8 million in 2021, then soared by 31.11% to $793.0 million in 2022, then surged by 37.83% to $1.1 billion in 2023, then soared by 44.82% to $1.6 billion in 2024.